The results of this study should encourage the use of Gal-3 as a biomarker for predictive and prognostic enrichment in AKI-related trials and test the impact of Gal-3 inhibition on outcomes in critically ill patients and elevated plasma Gal-3 levels. The gene discussed is LGALS3; the disease is acute kidney injury.